US Longevity Laboratories, Inc.
323-359-5210
A curated aggregator reporting only on longevity, anti-aging, and AI-driven healthspan science — sourced from the institutions and governments driving the field, with a dedicated dossier on Dr. David Sinclair of Harvard University.
Tenured Professor, Department of Genetics — Paul F. Glenn Center for Biology of Aging Research, Harvard Medical School
David Sinclair is best known for his work on understanding why we age and how to slow its effects. He obtained his Ph.D. in Molecular Genetics at the University of New South Wales in 1995 and trained as a postdoctoral researcher at M.I.T. with Dr. Leonard Guarente, where he co-discovered a cause of aging in yeast and the role of Sir2 in epigenetic changes driven by genome instability. In 1999 he joined Harvard Medical School, where he has taught aging biology and translational medicine for over two decades. He is co-founder of several biotechnology companies, co-founder and co-chief editor of the journal Aging, an inventor on over 50 patents, and a recipient of more than 35 awards — including TIME's "100 Most Influential People in the World."
Sinclair's personal regimen targets the hallmarks of aging: 1g NMN and 1g resveratrol daily, plus metformin, spermidine, quercetin and vitamins D3/K2 — each backed by his lab's research on NAD+, sirtuins and senescence.
Source: NMN.comThe NICE mouse (neuronal inducible changes in the epigenome) models epigenetic changes in the aging brain. The lab targets drivers of neuronal degeneration to prevent, slow, or reverse diseases like Alzheimer's.
Source: The Sinclair Lab, Harvard Medical SchoolAn NIH Director's Pioneer Award pipeline combining math, proteomics, mass spectrometry and high-throughput screening to discover thousands of putative peptide-coding genes — potential hormones to treat common and rare diseases.
Source: The Sinclair Lab, Harvard Medical SchoolUsing reprogramming factors to reset a cell's epigenetic state and reverse its age. Human-compatible viral vectors deliver the factors to tissues, accelerating wound healing and nerve regeneration — with companion-animal and human therapies in view.
Source: The Sinclair Lab, Harvard Medical SchoolProposes that aging is driven by the loss of epigenetic information — that cells lose their identity over time — and that this process is reversible. The foundation for Sinclair's age-reversal research.
Source: The Sinclair Lab, Harvard Medical SchoolUsing ovarian stem cells and aging/metabolism insights to reactivate oocyte production — aiming to treat premature ovarian failure, chemotherapy-induced infertility, and extend the healthy fertile period for women.
Source: The Sinclair Lab, Harvard Medical SchoolNAD+ levels decline with age, reducing SIRT1 activity and DNA repair. The lab studies NAD+-boosting molecules (e.g. NMN) to restore healthspan; human clinical trials are ongoing.
Source: The Sinclair Lab, Harvard Medical SchoolMiscommunication between the nuclear and mitochondrial genomes drives age-related physiological decline. Mitochondrial NAD+ levels dictate cell survival, and NAD+ leakage from mitochondria may cause aging and memory loss.
Source: The Sinclair Lab, Harvard Medical SchoolThe Relocalization of Chromatin Modifiers hypothesis: DNA damage pulls epigenetic regulators away from their genes, causing lasting gene-expression changes. The inducible ICE mouse model accelerates and studies this aging process.
Source: The Sinclair Lab, Harvard Medical SchoolDiscovery of small molecules that activate SIRT1 — starting with resveratrol in 2003. Potent STACs have since entered clinical trials with positive results, targeting multiple age-related diseases with a single mechanism.
Source: The Sinclair Lab, Harvard Medical SchoolEvery item is traced to its originating institution or government body — from Dubai's Longevity Authority to AI geroscience labs — so you always know the source.
A roundup of leading longevity biotech companies — including Altos Labs, Cambrian Bio, Junevity and BioAge Labs — advancing cellular reprogramming, senolytics and AI-driven drug discovery.
His Highness Sheikh Mohammed bin Rashid issued Law No. 17 of 2026 establishing the Dubai Longevity Authority (DLA), a dedicated regulator to position the emirate as a global hub for longevity, wellness and advanced health.
The full legislation establishing the DLA, mandating healthy-ageing promotion, preventive healthcare, and scientific research to make Dubai the world's leading hub for regulated longevity and cellular therapies.
The first cellular-reprogramming treatment aimed at reversing aging was administered to a human patient — a milestone for the reprogramming frontier of longevity science.
Sinclair's personal regimen targets the hallmarks of aging: 1g NMN and 1g resveratrol daily, plus metformin, spermidine, quercetin and vitamins D3/K2 — each backed by his lab's research on NAD+, sirtuins and senescence.
Industry leaders at the Breakthrough Technology Summit discuss how AI is re-framing what it means to age and accelerating advances in anti-aging medicine and healthspan research.
A synthesis from the Aging Research and Drug Discovery meeting — led by Insilico Medicine (Abu Dhabi) and the University of Copenhagen — on how AI identifies precise aging biomarkers, builds 'aging clocks,' and accelerates drugs targeting primary aging drivers.
The NICE mouse (neuronal inducible changes in the epigenome) models epigenetic changes in the aging brain. The lab targets drivers of neuronal degeneration to prevent, slow, or reverse diseases like Alzheimer's.
An NIH Director's Pioneer Award pipeline combining math, proteomics, mass spectrometry and high-throughput screening to discover thousands of putative peptide-coding genes — potential hormones to treat common and rare diseases.
Using reprogramming factors to reset a cell's epigenetic state and reverse its age. Human-compatible viral vectors deliver the factors to tissues, accelerating wound healing and nerve regeneration — with companion-animal and human therapies in view.
Proposes that aging is driven by the loss of epigenetic information — that cells lose their identity over time — and that this process is reversible. The foundation for Sinclair's age-reversal research.
Using ovarian stem cells and aging/metabolism insights to reactivate oocyte production — aiming to treat premature ovarian failure, chemotherapy-induced infertility, and extend the healthy fertile period for women.
NAD+ levels decline with age, reducing SIRT1 activity and DNA repair. The lab studies NAD+-boosting molecules (e.g. NMN) to restore healthspan; human clinical trials are ongoing.
Miscommunication between the nuclear and mitochondrial genomes drives age-related physiological decline. Mitochondrial NAD+ levels dictate cell survival, and NAD+ leakage from mitochondria may cause aging and memory loss.
The Relocalization of Chromatin Modifiers hypothesis: DNA damage pulls epigenetic regulators away from their genes, causing lasting gene-expression changes. The inducible ICE mouse model accelerates and studies this aging process.
Discovery of small molecules that activate SIRT1 — starting with resveratrol in 2003. Potent STACs have since entered clinical trials with positive results, targeting multiple age-related diseases with a single mechanism.